BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27537780)

  • 1. A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis.
    Zuo P; Dobbins RL; O'Connor-Semmes RL; Young MA
    CPT Pharmacometrics Syst Pharmacol; 2016 Aug; 5(8):418-26. PubMed ID: 27537780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.
    Lanzini A; De Tavonatti MG; Panarotto B; Scalia S; Mora A; Benini F; Baisini O; Lanzarotto F
    Gut; 2003 Sep; 52(9):1371-5. PubMed ID: 12912872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
    Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
    J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
    Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
    Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
    Van Hoogstraten HJ; De Smet MB; Renooij W; Breed JG; Engels LG; Den Ouden-Muller JW; Rijk MC; Smit AM; Zwertbroek R; Hop WC; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Aliment Pharmacol Ther; 1998 Oct; 12(10):965-71. PubMed ID: 9798800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
    Eriksson LS; Olsson R; Glauman H; Prytz H; Befrits R; Rydén BO; Einarsson K; Lindgren S; Wallerstedt S; Wedén M
    Scand J Gastroenterol; 1997 Feb; 32(2):179-86. PubMed ID: 9051880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A; Jazrawi RP; Ahmed HA; Davis T; Bland JM; Benson M; Orchard RT; Theodossi A; Maxwell JD; Northfield TC
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
    Nikolovska D; Vasilev P; Mikhova A
    Vutr Boles; 2000; 32(1):25-7. PubMed ID: 11195193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
    Combes B; Carithers RL; Maddrey WC; Munoz S; Garcia-Tsao G; Bonner GF; Boyer JL; Luketic VA; Shiffman ML; Peters MG; White H; Zetterman RK; Risser R; Rossi SS; Hofmann AF
    Hepatology; 1999 Jun; 29(6):1649-54. PubMed ID: 10347103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [-Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy-].
    Rudi J; Schönig T; Stremmel W
    Z Gastroenterol; 1996 Mar; 34(3):188-91. PubMed ID: 8650973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis.
    Roda E; Azzaroli F; Nigro G; Piazza F; Jaboli F; Ferrara F; Liva S; Giovanelli S; Miracolo A; Colecchia A; Festi D; Mazzeo C; Bacchi L; Roda A; Mazzella G
    Dig Liver Dis; 2002 Jul; 34(7):523-7. PubMed ID: 12236487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
    Bosch A; Dumortier J; Maucort-Boulch D; Scoazec JY; Wendum D; Conti F; Morard I; Rubbia-Brandt L; Terris B; Radenne S; Abenavoli L; Poupon R; Chazouillères O; Calmus Y; Boillot O; Giostra E; Corpechot C
    J Hepatol; 2015 Dec; 63(6):1449-58. PubMed ID: 26282232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.
    Verma A; Maxwell JD; Ang L; Davis T; Hodges S; Northfield TC; Zaidi M; Pazianas M
    Osteoporos Int; 2002 Aug; 13(8):677-82. PubMed ID: 12181628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate treatment: a new medical approach for PBC patients?
    Kanda T; Yokosuka O; Imazeki F; Saisho H
    J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
    Combes B; Emerson SS; Flye NL; Munoz SJ; Luketic VA; Mayo MJ; McCashland TM; Zetterman RK; Peters MG; Di Bisceglie AM; Benner KG; Kowdley KV; Carithers RL; Rosoff L; Garcia-Tsao G; Boyer JL; Boyer TD; Martinez EJ; Bass NM; Lake JR; Barnes DS; Bonacini M; Lindsay KL; Mills AS; Markin RS; Rubin R; West AB; Wheeler DE; Contos MJ; Hofmann AF
    Hepatology; 2005 Nov; 42(5):1184-93. PubMed ID: 16250039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis.
    Marschall HU; Broomé U; Einarsson C; Alvelius G; Thomas HG; Matern S
    J Lipid Res; 2001 May; 42(5):735-42. PubMed ID: 11352980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the efficacy of ursodeoxycholic acid and bile acid metabolism between viral liver diseases and primary biliary cirrhosis.
    Nakashima T; Yoh T; Sumida Y; Kakisaka Y; Mitsuyoshi H
    J Gastroenterol Hepatol; 2001 May; 16(5):541-7. PubMed ID: 11350551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.